PATENT CLAIM ANALYSIS

Application Number: 16033071
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claim (Index 20):
A method for the treatment of a disorder associated with LRRK2 kinase dysfunction in a mammal, the method comprising the step of administering to the mammal an effective amount of at least one compound having a structure represented by a formula: wherein Z is selected from N and CR 20 ;\n wherein each occurrence of R 20 , when present, is independently selected from hydrogen, \u2014CN, \u2014F, \u2014Cl, \u2014CF 3 , and C1-C4 alkyl; \n wherein R 1  is selected from Cy 1 , Ar 2 , \u2014CR 21a R 21b Cy 2 , and \u2014CR 21a R 21b Ar 2 ;\n wherein each of R 21a  and R 21b , when present, are independently selected from hydrogen and C1-C4 alkyl; \n wherein Cy 1 , when present, is selected from C3-C5 cycloalkyl and 2,3-dihydroindene and is substituted with 0, 1, or 2 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; \n wherein Cy 2 , when present, is selected from C3-C6 cycloalkyl, C2-C5 heterocycloalkyl, and 2,3-dihydroindene and is substituted with 0, 1, or 2 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; \n wherein Ar 2 , when present, is selected from C5-C6 aryl and C4-C5 heteroaryl and is substituted with 0, 1, or 2 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; and \n wherein each of R 2 , R 3 , and R 4  are independently selected from hydrogen and C1-C4 alkyl; wherein Ar 1  is a structure selected from: wherein A is selected from NR 22  and CR 23a R 23b ;\n wherein R 22 , when present, is selected from hydrogen, halogen, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 hydroxyalkyl, C1-C8 alkoxyalkyl, \u2014(C1-C8 alkyl)NH 2 , \u2014(C1-C8 alkyl)NH(C1-C8alkyl), \u2014(C1-C8 alkyl)N(C1-C8 alkyl)(C1-C8 alkyl), C1-C8 alkylacid, \u2014(C1-C4 alkyl)CONH 2 , \u2014(C1-C4 alkyl)CONH(C1-C4 alkyl), \u2014(C1-C4 alkyl)CON(C1-C4 alkyl)(C1-C4 alkyl), \u2014(C1-C4 alkyl)(C\u2550O)Cy 3 , and Cy 3 ;\n wherein each occurrence of Cy 3 , when present, is independently selected from C3-C6 cycloalkyl and C2-C5 heterocycloalkyl and is substituted with 0, 1, or 2 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; \n \n wherein each of R 23a  and R 23b , when present, is independently selected from hydrogen, halogen, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 hydroxyalkyl, C1-C8 alkoxyalkyl, C1-C8 alkylacid, \u2014(C1-C4 alkyl)(C\u2550O)Cy 1 , \u2014(C1-C4 alkyl)CONH 2 , \u2014(C1-C4 alkyl)CONH(C1-C4 alkyl), \u2014(C1-C4 alkyl)CON(C1-C4 alkyl)(C1-C4 alkyl), and Cy 3 ; \n wherein each of Q 1 , Q 2 , and Q 3  is independently selected from N and CR 24 ; and\n wherein each occurrence of R 24 , when present, is independently selected from hydrogen, halogen, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxyalkyl, \u2014(C1-C4 alkyl)CONH 2 , \u2014(C1-C4 alkyl)CONH(C1-C4 alkyl), \u2014(C1-C4 alkyl)CON(C1-C4 alkyl)(C1-C4 alkyl), \n provided that two or three of A, Q 1 , Q 2 , and Q 3  are N, or a pharmaceutically acceptable salt thereof, wherein the disorder is selected from a neurodegenerative disorder and leprosy.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 95.0
- Lexical Diversity: 1.68421
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15519109', '15039763', '13922230', '14913266', '13420333']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8141424597456625
- 35 USC 102 Novelty (BERT): 0.5564380017008661
- Combined Prediction Score: 0.7883720139411828
- Mean Citation Score: 395.80136
- Max Citation Score: 458.08496
- Similarity Product: 320.9625135388375

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test